BridgeBio Oncology Therapeutics, which was spun out of BridgeBio Pharma (NASDAQ:BBIO) last year, has agreed to merge with Helix Acquisition Corp. II (NASDAQ:HLXB), a Boston-headquartered SPAC, to ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Monday, February 24th. Leerink Partnrs analyst M.

Citi raised the firm’s price target on BridgeBio (BBIO) to $49 from $45 and keeps a Buy rating on the shares following the Q4 report. As of ...

BRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Thursday, February 20th. The company reported earnings of -$1.31 per share, missing estimates of -$1.15 ...

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...